目的：探讨成骨细胞特异性转录因子2(runt-related transcription factor 2，Runx2)在乳腺癌组织中的表达及临床意义。方法：采用免疫组织化学法检测Runx2在乳腺浸润性导管癌和癌旁乳腺组织中的表达情况及其与乳腺癌临床病理特征间的关系。结果：Runx2在乳腺浸润性导管癌及癌旁乳腺组织中的阳性表达率分别为69.52%(73/105)和8.57%(9/105)，乳腺浸润性导管癌组Runx2的阳性表达率显著高于癌旁乳腺组织，差异具有统计学意义，而且Runx2在乳腺浸润性导管癌中的表达与雌激素受体(estrogen receptor，ER)呈负相关。Runx2的表达与乳腺癌的组织学分级、淋巴结转移及临床分期相关，而与患者年龄及肿瘤大小无关。结论：Runx2可能参与了乳腺癌的发生，而且在ER阴性乳腺癌的发生过程中可能发挥了更加重要的作用。Runx2与乳腺癌的恶性程度、浸润、转移有关，提示Runx2可能成为乳腺癌患者预后评估的重要指标之一。
Expression and clinical significance of runt-related transcription factor 2 in breast carcinoma
Objective: To study the expression and clinical significance of runt-related transcription factor 2 (Runx2) in breast carcinoma. Methods: The expression of Runx2 in primary breast invasive ductal carcinoma (IDC) and adjacent mammary gland tissue and its relationship with breast cancer’s clinical pathological features was detected by immunohistochemical method (IHC). Results: IHC analysis showed that the positive expression rate of Runx2 in IDC was 69.52% (73/105), much higher than that in para-tumor breast tissues [8.57% (9/105), P<0.05] and the expression of Runx2 in IDC was negatively related with estrogen receptor (ER). Furthermore, Runx2 expression showed a significant correlation with histopathologic grade lymph node metastasis and pTNM stage, and did not correlate with patients’ age, and tumor size. Conclusion: The overexpression of Runx2 may participate in the tumorigenesis of breast carcinoma and may play a more important role in the carcinogenesis of ER negative-expressing breast carcinoma. Runx2 correlated with malignant degree, invasion and metastasis of breast carcinoma and may be a key factor to assess the prognosis of patients.